bluuebunny/crossref_metadata_2025_split huggingface dataset:
Secondary Hodgkin's disease in childhood acute lymphoblastic leukemia
Authors: Peeters Marie A. , Smith Charles , Saunders E. Fred. 
Published: February 2007

AbstractImproved survival in childhood acute lymphoblastic leukemia has led to the occurrence of second malignancies in these patients. Hodgkin's disease is very rare as a second malignancy. We report three patients with acute lymphoblastic leukemia in remission who developed Hodgkin's disease. Although all had received low‐dose irradiation, none received alkylating agents as part of their chemotherapy. Review of our cases and of 11 reported in the literature revealed unique aspects of this association. There was a short median interval of 19 months to the development of the second malignancy. Over one‐third of the patients had uncommon sites of involvement (lung, tonsil, small bowel). The distribution of histologic subtypes was unusual, as 5 of 14 cases had lymphocyte depletion or unclassifiable Hodgkin's disease. The results of therapy were excellent. Our three patients are alive, with both malignancies in continuing remission. Two patients are off all therapy for 4 and 6 years, respectively. The third remains on antileukemic treatment. Secondary Hodgkin's disease in childhood acute lymphoblastic leukemia does not appear to have a poor prognosis and long‐term survival and possible cure of both diseases may be achieved.
Massive adrenal hemorrhage secondary to metastatic lung carcinoma
Authors: Rowinsky Eric K. , Jones Richard J. , Abeloff Martin D. 
Published: February 2007

AbstractThe adrenal glands are frequently metastatic sites of lung and other primary neoplasms. These metastases are usually clinically occult and secondary adrenal hemorrhage is extremely rare. Two patients who developed massive adrenal hemorrhage seconday to metastatic lung carcinoma to the adrenal glands are presented.
Infections in patients with non‐small‐cell lung cancer treated with intensive induction chemotherapy
Authors: Fuks Joachim Z. , Patel Halesh , Hornedo Javier , Van Echo David A. , Moody Mark , Aisner Joseph 
Published: February 2007

AbstractThe records of 65 consecutive patients with non‐small‐cell lung cancer (NSCLC) treated with intensive induction chemotherapy were reviewed to study the infectious complications during therapy and to analyze the relationship of the frequency of infections to various predisposing factors. A total of 44 infectious episodes were observed among 30 of the 65 patients. Of the 44 infections, 18 were microbiologically documented and 19 clinically. Seven (16%) infections were without microbiological or clinical documentation and were categorized as “possible” infections. Among the 18 microbiologically documented infections, fifteen (83%) were caused by bacteria and three by fungi. The most frequent bacteria identified in 11 (61%) of the 18 infections were gram‐negative organisms, Escherichia coli and Klebsiella pneumoniae being the most frequent. Eight of the 44 infections were associated with bacteremia and three with microbiologically documented pneumonias. There were three drug‐related infectious deaths, two associated with bacteremia and one with possible infections. All 44 infectious episodes presented with WBC counts of <1,000/μil, and 34 (79%) had WBC counts of <500/μl. We observed that during therapy, patients with poor performance status (< 80%) are at a much higher risk to develop infectious complications than those with good performance status (>80%; p <.001).Although encouraging responses with intensive chemotherapy have been reported for NSCLC in several studies, a major impact of chemotherapy on the survival of patients with this disease has yet not been established. Thus, intensive chemotherapy for NSCLC should remain an experimental treatment modality and should be offered only to patients with good prognostic factors such as those defined by pretreatment performance status.
Aggressive infantile myofibromatosis: Report of a case of a clinically progressive congenital multiple fibromatosis
Authors: Molnar Peter , Olah Eva , Miko Tivadar L. , Gomba Szabolcs 
Published: February 2007

AbstractWe report a case of congenital multiple fibromatosis (infantile myofibromatosis) showing the typical spindle‐cellular proliferation with prominent vascularity on light microscopical observations. Electron microscopy showed the abundance of fibroblasts with conspicuous collagen and reticulin fibers together with numerous cells sharing the characteristics of both fibroblasts and smooth muscle cells (myofibroblasts). Neither visceral involvement nor ossification has been detected during the 4‐year‐long follow‐up period. However, the clinical course has shown a slow, continuous, protracted though destructive proliferation of subcutaneous myofibroblastic nodules. These findings are contrasted with previous reports that claimed that the presence of myofibroblasts indicates benign behavior and results in the regression of fibromatous lesions.
Health status of young children with cancer following discontinuation of therapy
Authors: Pastore G. , Zurlo M. G. , Acquaviva A. , Calculli G. , Castello M. , Ceci A. , Di Tullio M. L. , Gandus S. , Macchia P. , Di Montezemolo L. Cordero , Mandelli F. , Massolo F. , Nespoli L. , Paolucci G. , Rosate M. , Senesi E. , Tamaro P. , Tripoli U. , Terracini B. 
Published: February 2007

AbstractThis paper reports late effects and health status of 198 children who had cancer or leukemia diagnosed under 2 years of age and their therapies electively withdrawn. This series (92 neuroblastoma [NBL], 57 Wilms' tumor [WT], 46 acute lymphoblastic leukemia [ALL], and 3 non‐Hodgkin's lymphomal was followed for 1‐12 years after discontinuation of therapy. Thirty‐three children were diagnosed before 1973, 92 between 1973 and 1977, and 73 after 1977 in 16 Italian Pediatric Oncology Centers. As of December 1983, 176 children were reported to be alive and without evidence of primary cancer by physicians responsible for their care. One child died from a second primary tumor, two from late recurrences of the primary cancer, and three from other causes; eight were alive with evidence of primary cancer; and eight were lost to follow‐up. Kyphoscoliosis was found in 22 children and other musculoskeletal anomalies in 8. Neurological sequelae were observed in 8 out 35 children with ALL treated with radiotherapy (RT) and intrathecal methotrexate. All but one were in continous complete remission when they developed seizures (three cases), leukoencephalopathy (three cases), or intracerebral calcitications (two cases). One child had cardiomyopathy and subsequently died from cardiac failure: he had received doxorubicin (400 mg/m2) and mediastinal RT (13 Gy) for NBL. Growth impairments were observed in children with NBL and WT.
Randomised study of ticarcillin, cefamandole with or without tobramycin in febrile, neutropenic patients with solid tumors
Authors: Page Jonathan P. , Levi John A. , Woods Robert L. , Chan Wing K. , Bell David R. , Aroney Rodney S. 
Published: February 2007

AbstractA prospective randomised study was conducted comparing the efficacy and toxicity of the antibiotics ticarcillin and cefamandole (TC) with or without tobramycin (TCT) in 100 febrile neutropenic patients with solid tumours undergoing conventional chemotherapy. In this study, neutropenia <100/μMl was noted in 31% of 106 evaluable infectious episodes and neutrophil counts <1,000/μMl persisted for a median 4 days. Infection was microbiologically documented in 42% of episodes (bacteremia 24%) with gram‐negative organisms responsible for 63% of bacterial isolates. Overall, 65% of episodes responded to TC and 76% to TCT (p>0.05). Patients with initial shock bacteremia, pulmonary infection, or gram‐negative sepsis responded relatively poorly. Neutrophil nadir and pathogen susceptibility did not influence outcome. Antibiotic toxicity was minimal with no tobramycin‐related nephrotoxicity. These results are broadly comparable to those observed with leukemic patients, but the relatively short duration of neutropenia in the solid‐tumour patients appears to minimize the need for additional antibiotics provided there is adequate antimicrobial coverage with the initial choice of antibiotics.
Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: Future aspects
Authors: Sawada Tadashi , Sugimoto Tohru , Tanaka Terufusa , Kawakatsu Hidekazu , Ishii Takashi , Matsumura Takafumi , Horii Yoshihiro 
Published: February 2007

AbstractThe annual incidence of neuroblastoma in Japan, a common malignancy of young children which has a very poor prognosis in progressive cases, was previouly estimated to be 8.2 cases/million children under 15 years of age. Based on the Japanese National Census of the Population for 1982, the annual number of cases of this tumor is predicted to be 220. (Sawada et al: Med Pediatr Oncol 12:101‐103, 1984). Before the mass screening program was started, one‐fourth of all neuroblastoma cases were detected before the age of one by clinical symptoms and other findings.Since 1974, a neuroblastoma mass screening program for 6‐month‐old infants by means of a qualitative Vanilmandelic Acid (VMA) test has been in effect in Kyoto, Japan, for the prognostic improvement of neuroblastoma patients (Sawada et al: Am J Dis Child 136:710‐712, 1982). A Neuroblastoma Mass Screening Study Group (NBMSSG) was organized in 1981 (Sawada et al: Lancet ii:271‐272, 1984), and the mass screening program has grown to encompass eight selected areas. This group discovered 15 cases of neuroblastoma among 247,500 6‐month‐old infants, 1 of every 16,500, until the end of 1983, and 23 cases among 434,970, 1 of every 18,900, until the end of 1984. All cases were asymptomatic. As the incidence of infantile neuroblastoma detected by this program is projected to be 52.9‐60.6 cases/million 6‐month‐old infants, it could be predicted that 80‐91 neuroblastoma cases will be discovered annually in Japan by mass screening. The cure rate of 25 cases discovered by the mass screening and followed up over 20 months was 92% (Sawada: Lancet i:377, 1986).In Japan, it should be possible to detect 135‐146 cases‐[symptomatic 55 = 220 × 1/4] + [80‐91 cases detected by mass screening]‐(61.4‐66.4% of the total neuroblastoma cases) in infants under 1 year of age annually, and the cure rate of all neuroblastoma cases in Japan is expected to reach 60% or more.
Chronic myeloid leukemia: Manifesting as spontaneous splenic rupture and terminating in megakaryoblastic transformation
Authors: Shih Lee‐Yung , Su Ih‐Jen 
Published: February 2007

AbstractWe report a case of chronic myeloid leukemia with spontaneous splenic rupture as the initial presenting feature; there was a successful surgical outcome, but this case terminated in megakaryoblastic transformation. Results are reported based on morphological, immunological, cytochemical, ultrastructural, immunocytochemical studies, and in vitro liquid culture studies. The megakaryocytic nature of the blast cells was identified through the demonstration of platelet peroxidase activity by ultrastructural cytochemistry and the presence of platelet and megakaryocyte‐specific antigen using monoclonal antibody, as well as the anti‐factor VIII antibody by immunocy‐tochemical technique.
Transient myeloproliferative disorder in chromosomally normal newborn infant
Authors: Kalousek D. K. , Chan K. W. 
Published: February 2007

AbstractTransient Myeloproliferative disorder is a condition clinically resembling congenital acute myelogenous leukemia. As in acute leukemias the blast cell population in this disorder may have either normal or abnormal chromosomal complement. Transient myeloproliferative disorder is well recognized in neonates with a complete or mosaic trisomy 21 (Down's syndrome). We report a phenotypically and cytogenetically normal infant with this syndrome in whom only blast cells showed trisomy 21. We postulate that the pathogenesis of the transient myeloproliferative disorder in both Down's syndrome infants and those with a normal chromosomal complement is related to abnormal prenatal production of placental regulatory hemopoietic factors caused by chromosomal defect(s) confined to placental tissues.
Salvage chemotherapy for advanced Hodgkin's disease
Authors: Garbes Isosceles D. , Gomez German A. , Han Tin , Henderson Edward S. 
Published: February 2007

AbstractEleven patients with Hodgkin's disease refractory to chemotherapy were treated with six cycles of intermediate‐dose methotrexate with calcium leucovorin rescue, followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (MTX‐CHOP). Three other patients were treated with a similar program of treatment minus doxorubicin (MTX‐COP). The overall response rate was 57%, with four (29%) patients achieving a complete response and four patients achieving a partial response. None of the three patients treated with MTX‐COP had a complete remission (CR); thus the complete remission rate with MTX‐CHOP was somewhat higher (36%). Only one of the CR's is in continuous complete remission and free of disease at 99+ months. One patient died of overwhelming sepsis and pancytopenia during treatment. Hematologic toxicity in the other patients was acceptable. The overall median survival was 18 months. The search for an effective treatment program for this group of patients remains a major challenge.
Siblings of paediatric cancer patients: A population at risk
Authors: Carr‐Gregg Michael , White Les 
Published: February 2007

AbstractThe psychosocial care of children with cancer has received increasing and welcome emphasis in the medical literature. However, the current and future status of siblings of such patients has been an underestimated area of concern. We examine the general importance of sibling relationships and present the literature regarding siblings of paediatric oncology patients. Donors and recipients of bone marrow transplants are considered specifically. Preliminary results of original research, supported by available published studies, suggest important disturbances in the mental health of siblings. Implications for paediatricians and other health professionals as well as prevention and intervention strategies are indicated.
Neuroblastoma overview—1986
Authors: D'Angio Giulio J. 
Published: February 2007

AbstractUnderstanding of the biology of neuroblastoma has advanced dramatically in the last several decades. Misunderstood and misdiagnosed in the early years of this century, neuroblastoma is now the prototypic model for research in the molecular biology and genetics of the transformed cell. It is through these advances in knowledge of the malignant process, and of neuroblastoma itself, that exquisitely targeted therapies will shortly evolve. These include not only immunologic approaches through monoclonal antibodies, I but also the exploitation of metabolic pathways. Radioactive meta‐iodobenzylguanidine (MIBG) is among the most promising of the latter methods. It is deservedly undergoing clinical tests for its diagnostic and therapeutic applications in the management of neuroblastoma patients.
Radiochemistry, biochemistry, and kinetics of 131I‐metaiodobenzylguanidine (MIBG) and 123I‐MIBG: Clinical implications of the use of 123I‐MIBG
Authors: Shapiro B. , Gross M. D. 
Published: February 2007

AbstractMetaiodobenzylguanidine (MIBG) is actively concentrated in adrenergic neuroendocrine tissues and tumors by an active, energyand sodium‐dependent, high‐affinity, saturable mechanism. This has proved successful, when labeled with 131‐l or 123‐l, in scintigraphically depicting pheochromocytomas and neuroblastomas.For imaging purposes 123‐l has multiple advantages over 131‐l; the gamma ray energy is ideal for modern instruments the decay by electron capture limits the particulate emissions, and the short half‐life reduces the radiation burden. It is thus possible to use doses of 123‐I‐MIBC 20 times as large as doses of 131‐I‐MIBG with equivalent absorbed radiation doses. Disadvantages of 123‐I include the cost and difficulties in the regular delivery of this short‐lived radionuclide.For most imaging purposes 123‐I‐MIBC is the optimal agent if logistical problems in its sup ply can be overcome.
Treatment of neuroblastoma with 131I‐MIBG: Dosimetric problems and perspectives
Authors: Beierwaltes William H. 
Published: February 2007

AbstractBetween 7/3/80 and 5/7/86 we gave 32 of our neuroblastoma patients 62 diagnostic doses of metaiodobenzylguanidine (MIBG) and 12 patients 20 treatment doses. Our conclusion from our diagnostic dose studies is that MIBG should be used for staging the extent of neu‐roblastoma before therapy is started, because it may change the proposed staging and therapy. In MIBG therapy for neuroblastoma, our criteria for agreeing to treat a patient are based on calculations from a 4‐day tracer dose study that assures that the patient will receive from his first therapy dose a tumor dose of at least 2,000 rads/100mCi, with a total body dose of not greater than 200 rads. Under these circumstances in children, the blood dose has been about 50 rads. The platelet count falls routinely with a 150‐rad whole‐body dose but never to dangerous levels. We have delivered tumor doses of 7,000‐34,600 rads on the first dose using 150‐215 mCi. We have had objective regressions (as shown by before and after CAT scans) of 30‐59% in volume of the principal tumor mass in 3 of the first 12 patients treated. All patients had Grade IV neuroblastoma with extensive previous surgery, radiation, and chemotherapy, with and without previous bone marrow transplants. MIBG therapy was most effective in patients with slower‐growing tumors for whom initial treatment doses were 200 mCi or more.
Therapeutic use of 131I‐metaiodobenzylguanidine (MIBG) in neuroblastoma: A phase II study in nine patients
Authors: Hartmann O. , Lumbroso J. , Lemerle J. , Schlumberger M. , Ricard M. , Aubert B. , Coonaert S. , Merline L. , Olive D. , De Lumley L. , Parmentier C. 
Published: February 2007

AbstractEffects of high activities of I 131 meta‐iodo‐benzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty‐two doses of mIBG labeled with 1.3 to 4 GBq (35‐108 mCi) of iodine 131 were administered. Three subjective effects, especially relief of pain, and two objective effects were observed. Transient blood pressure increase was observed once and did not recur after prolongation of the infusion time to 6 hours. A major side effect was bone marrow toxicity, essentially marked by thrombopenia, particularly severe in previously bone‐marrow‐transplanted patients.
Considerations on 131I‐metaiodobenzylguanidine therapy of six children with neuroblastoma
Authors: Sanguineti Michele 
Published: February 2007

AbstractSix children affected by neuroblastoma at stages III and IV were treated with high‐specific‐activity 131I‐metaiodobenzylguanidine (MIBG). After 131I‐MIBG treatment three patients died at 12, 10, and 12 weeks, respectively; the other three were still living at 21, 16, and 24 weeks, respectively.Although the assumptions for this therapy were propitious, the results obtained do not correspond to those expected. It is supposed that large tumor volume and previous chemotherapy and/or radiotherapy may impair the effectiveness of 131I‐MIBG therapy. Consequently, 131I‐MIBG therapy is recommended even if the spread of disease is not proved—only, however, when the tumor is small.
131I‐metaiodobenzylguanidine treatment in neuroblastoma: Report of two cases
Authors: Cottino F. , Mussa G. C. , Madon E. , Favero A. , Silvestro L. , Grazia G. 
Published: February 2007

AbstractPoor results with 131I‐meta‐iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1‐month‐spaced courses, respectively; cumulative administration of 11.9 and 9.2 GBq) has been characterized by a low isotope concentration in the primary tumor and in the multiple bone metastases and by bone marrow uptake with final severe hematological toxicity. A slight decrease in the primary tumor's volume was observed in one patient at a cumulative dose of 85 Gy; there was no change in the other's at 42 Gy. At an initial, greater isotope concentration delivering 103 Gy, some bone metastases displayed a sharp decrease in uptake that persisted in the successive courses. For both patients a progressive spreading of new tumor localisation in the bones and finally in the soft tissues was observed.
Cytoreductive procedures in the early management in cases of leukemia and hyperleukocytosis in children
Authors: Bunin Nancy J. , Kunkel Keith , Callihan Thomas R. 
Published: February 2007

AbstractCytoreduction for hyperleukocytosis before the initiation of primary therapy may reduce morbidity and mortality from blast cell lysis in children with acute lymphoblastic leukemia (ALL) and from leukostasis in children with acute nonlymphoblastic leukemia (ANLL) or chronic myelogenous leukemia (CML). The clinical features of 35 children (23 with ALL, 5 with ANLL, and 7 with CML) who underwent cytoreduction before the institution of definitive therapy were studied. Twelve children had exchange transfusions and 23 underwent leukaphereses. The cytoreductive procedures were equally effective in removing peripheral leukocytes (median decrease, 60%) and produced no complications. Ten children required additional cytoreduction because of further leukocyte increase before chemotherapy became effective. Three children with ALL who had renal insufficiency and metabolic derangement prior to leukapheresis sub‐sequently required additional therapeutic measures. Three children with respiratory symptoms attributable to leukostasis improved after cytoreducation, and there were no episodes of intracerebral hemorrhage. These observations demonstrate the safety and efficiency of exchange transfusion and leukapheresis, and provide support for the role of cytoreduction in the early management of cases of hyperleukostasis and leukemia in children.
Long‐term survival in patients with Ewing's sarcoma relapsing after completing therapy
Authors: Hayes F. A. , Thompson E. I. , Kumar M. , Hustu H. O. 
Published: February 2007

AbstractWhile the proportion of patients with Ewing's sarcoma attaining and maintaining long‐term remission has markedly improved, a proportion of patients suffer relapse of the tumor. In our experience relapses may occur late in the course of the disease, approximately 20% of those at risk beyond 5 years having recurrence of tumor.Review of our data indicates that for patients relapsing after therapy has been discontinued, the probability of attaining second remission is high (0.84) and that a significant proportion of these patients attaining second complete remission will survive their disease (0.60).
Leiomyosarcoma of the kidney: Report of a patient with favorable response to doxorubicin and cisplatin suspended in a lipid contrast medium and cyclophosphamide
Authors: Taniguchi Hiroki , Takahashi Toshio , Fujita Yoshihiro , Sakita Masakazu , Ogita Shuhei , Sawai Kiyoshi , Yamaguchi Toshiharu , Yokota Takashi , Nakagawa Noboru , Shimotsuma Masataka , Kondo Shinji 
Published: February 2007

AbstractA man who had unresectable leiomyosarcoma of the left kidney with skin and lung metastases was treated with intra‐arterial infusion chemotherapy consisting of cisplatin and doxorubicin suspended in lipid contrast medium, lipiodol, and oral administration of cyclophosphamide. The tumor responded well to this treatment three times. He is alive and well in remission, the renal tumor decreased in size, and lung metastases became unclear more than 50 weeks after treatment was completed.